Price
725.95
-0.62%52W Range
Market Cap
₹10,838.59 Cr
Traded: ₹6.99 Cr (0.06%) 0.0x
Free Float: ₹1,533.66 Cr (0.46% of FF traded)
Volume · 60D trend
96.29 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +16.0% | +20.0% | +15.0% | -- | +15.0% | Stable |
| ROE | -1.0% | +4.0% | +4.0% | -- | -- | Stable |
| Return | +14.0% | +28.0% | +28.0% | +9.0% | -- | Stable |
| Profit | +39.0% | +18.0% | -1.0% | -- | -36.0% | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 652 | 633 | 647 | 613 | 585 | 559 | 554 | 526 | 495 | 470 | 487 | 461 | 442 | 425 | 420 |
| Expenses | 573 | 527 | 524 | 524 | 505 | 480 | 470 | 451 | 435 | 403 | 391 | 402 | 386 | 365 | 349 | 345 |
| Operating Profit | 122 | 125 | 110 | 123 | 108 | 106 | 88 | 102 | 91 | 92 | 79 | 85 | 74 | 76 | 76 | 75 |
| OPM % | 18.0% | 19.0% | 17.0% | 19.0% | 18.0% | 18.0% | 16.0% | 18.0% | 17.0% | 19.0% | 17.0% | 17.0% | 16.0% | 17.3% | 17.8% | 18.0% |
| Other Income | 13 | -18 | -10 | 3 | 8 | 10 | 6 | 11 | 9 | 9 | 6 | 3 | 3 | 5 | 4 | 2 |
| Interest | 40 | 43 | 45 | 44 | 45 | 44 | 41 | 36 | 34 | 27 | 29 | 27 | 26 | 26 | 27 | 26 |
| Depreciation | 70 | 63 | 61 | 63 | 58 | 58 | 57 | 50 | 47 | 46 | 44 | 43 | 41 | 42 | 41 | 41 |
| Profit Before Tax | 25 | 1 | -6 | 20 | 12 | 14 | -3 | 28 | 19 | 28 | 11 | 18 | 11 | 13 | 11 | 10 |
| Tax % | 34.0% | -223.0% | 30.0% | -4.0% | 50.0% | 50.0% | -335.0% | 25.0% | 28.0% | 17.0% | 69.0% | 40.0% | 65.0% | 57.0% | 62.8% | 47.0% |
| Net Profit | 16 | 4 | -8 | 21 | 6 | 7 | 8 | 21 | 14 | 23 | 3 | 11 | 4 | 6 | 4 | 5 |
| Exceptional Items | -- | -32 | -13 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 0.9 | 0.1 | -0.6 | 1.1 | 0.3 | 0.5 | 0.5 | 1.2 | 0.8 | 1.4 | 0.4 | 0.9 | 0.5 | 0.6 | 0.5 | 0.5 |
| Sales Growth (YoY) | -- | 11.5% | 13.3% | 16.9% | 16.7% | 18.3% | 18.9% | 13.7% | 14.1% | 12.0% | 10.6% | 15.9% | 12.9% | 21.1% | -- | -- |
| Sales Growth (QoQ) | -- | 3.0% | -2.1% | 5.5% | 4.8% | 4.8% | 0.9% | 5.3% | 6.3% | 5.3% | -3.5% | 5.7% | 4.3% | 4.0% | 1.1% | -- |
| OP Growth (YoY) | 13.0% | 17.9% | 25.0% | 20.6% | 18.7% | 15.2% | 11.4% | 20.0% | 23.0% | 20.6% | 4.6% | 13.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | -2.4% | 13.6% | -10.6% | 13.9% | 1.9% | 20.5% | -13.7% | 12.1% | -1.1% | 16.5% | -7.1% | 14.9% | -3.0% | 1.1% | 0.7% | -- |
| Profit Growth (YoY) | -- | 162.0% | -117.0% | -10.0% | -61.0% | -61.0% | 22.0% | 33.0% | 59.0% | 123.0% | -24.0% | 84.0% | 26.0% | 40.0% | 170.0% | 37.9% |
| EPS Growth (YoY) | -- | -70.0% | -234.0% | -10.7% | -61.0% | -65.3% | 20.5% | 32.6% | 57.7% | 152.6% | -23.5% | 73.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 123.8% | -157.8% | 240.6% | -36.0% | 6.4% | -61.5% | 48.8% | -43.1% | 269.2% | -57.6% | 76.9% | -8.8% | 11.8% | -3.8% | -- |
| OP Margin | -- | 19.2% | 17.3% | 19.1% | 17.6% | 18.1% | 15.8% | 18.5% | 17.3% | 18.6% | 16.7% | 17.4% | 16.1% | 17.3% | 17.8% | 17.9% |
| Net Margin | -- | 0.6% | -1.3% | 3.2% | 1.0% | 1.2% | 1.4% | 3.7% | 2.6% | 4.7% | 0.7% | 2.2% | 0.8% | 1.3% | 1.0% | 1.2% |
| Material Cost % | -- | 27.1% | 27.9% | 27.4% | 26.4% | 26.3% | 26.7% | 26.1% | 25.4% | 24.8% | 24.3% | 24.8% | 25.6% | 26.4% | 25.3% | 24.4% |
| Employee Cost % | -- | 14.2% | 14.9% | 14.6% | 15.9% | 15.9% | 16.2% | 15.4% | 16.2% | 15.5% | 16.5% | 15.8% | 16.7% | 15.6% | 16.3% | 16.3% |
| P/S | 4.13 | 3.98 | 3.90 | 3.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 474.48 | 729.57 | 505.35 | 228.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 8.14 | 7.61 | 10.49 | 8.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find attached herewith the Transcript of Earnings Call held on August 07, 2026, with Analysts/Investors to discuss the Unaudited Financial Results (Standalone and Consolidated) of ....
Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, approved at the meeting of Board of Directors held ....
This is to inform you that the Audio recording of the Earnings Call with Analysts/Investors held on August 07, 2026, to discuss the Unaudited Financial Results (Standalone and Consolidated) ....
This is to inform that the Company will be participating in the group investor meeting hosted by Ambit Capital in Bangalore.
Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
The Board of Directors of the Company has approved a further investment of up to INR 16 Crores in HCG Rajkot Hospitals LLP, a wholly-owned subsidiary of the Company.
The Board of Directors has approved the re-appointment of M/s Rao Murthy & Associates, Cost Accountants as Cost Auditors of the Company for the financial year 2026-27.
Statement of Variation or Deviation for funds raised through Rights Issue for the quarter ended June 30, 2026.
Monitoring Agency Report for the quarter ended June 30, 2026, in relation to the Rights Issue of the Company..
Investor Presentation on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.
Press release on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.
The Company has announced the Outcome of the Board meeting held on August 06, 2026, including approval of unaudited financial results of the Company for the quarter ended June 30, 2026.
Further to the intimation submitted to Stock Exchanges dated July 27, 2026, with respect to the meeting of the Board of Directors of the Company, to be held on Thursday, August 06, 2026, ....
Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited ....
Newspaper Advertisement in respect of Special Window for Transfer and Dematerialisation of Physical Securities of the Company.
Scrutinizers report and Outcome of the Postal Ballot for the agenda(s) listed in the Postal Ballot Notice dated June 08, 2026, of the Company.
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026.
Intimation for closure of Trading Window under the SEBI (Prohibition of Insider Trading) Regulations, 2015, for the quarter ending June 30, 2026.
Intimation regarding completion of divestment by the Company of its entire shareholding in BACC Health Care Private Limited, subsidiary of the Company, pursuant to the Share Purchase Agreement ....
The Directorate General of Health Services, Central Drugs Standard Control Organization (Ethics Committee Division) has issued an order dated June 12, 2026, (received on June 16, 2026) ....
Newspaper Advertisement in respect of Special Window for Transfer and Dematerialisation of Physical Securities of the Company.
Newspaper advertisement of Postal Ballot Notice dated June 08, 2026, of the Company.
Please find enclosed the copy of Postal Ballot Notice together with Explanatory Statement dated June 08, 2026.
Please see attached herewith the Transcript of the Earnings Call held on May 20, 2026, with Analysts/Investors to discuss the Audited Financial Results (both Standalone & Consolidated) ....
Resignation of Interim CFO: Pursuant to the approval accorded by the Board of Directors at its meeting held on May 19, 2026, for the appointment of Mr. Sanjeev Kumar as the Chief Financial ....
Newspaper advertisement of Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026, approved at the meeting of Board of Directors ....
Pursuant to Listing Regulations, please find enclosed herewith the Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2026, issued by M/s V Sreedharan ....
Further to our intimation dated May 07, 2026, we would like to inform you that the Audio recording of the Earnings Call with Analysts/Investors held on May 20, 2026, to discuss the Audited ....
Statement of Deviation or Variation of the proceeds of Rights Issue for the quarter ended March 31, 2026.
Audited Financial Results for the quarter and year ended March 31, 2026.
The Board of Directors of the Company has approved the divestment by way of sale of its entire equity shareholding in its wholly owned subsidiary- BACC Health Care Private Limited to Inviga ....
The Board of Directors at their meeting held on May 19, 2026, has approved the appointment of Mr. Ravi Gothwal as AVP- Investor Relations, who shall be classified as a Senior Management ....
The Board of Directors of the Company at their meeting held on May 19, 2026, has approved the appointment of Mr. Sanjeev Kumar as the Chief Financial Officer and Key Managerial Personnel ....
Press release on Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.
The Board of Directors of the Company approved the re-appointment of Mr. Rajiv Maliwal (DIN: 00869035) as a Non-Executive Independent Director of the Company for a second term of 5 consecutive ....
The Board of Directors of the Company at their meeting held on May 19, 2026, has approved the re-appointment of Mr. Vijay S Shanbhag as the Internal Auditor of the Company under Section ....
The Company has entered into a Share Purchase Agreement with Inviga Healthcare Fund I in relation to the divestment by way of sale of the entire equity shares held by the Company in BACC ....
Investor Presentation on the Annual Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026.
The Company has announced the Outcome of the Board meeting held on May 19, 2026, including approval of audited financial results of the Company for the quarter and year ended March 31, 2026.
The Company hereby informs the exchanges that it has today launched its new comprehensive cancer hospital in Hebbal, with up to 132 beds, strengthening access to advanced oncology care ....
HealthCare Global Enterprises Limited (HCG), India''s largest dedicated cancer hospital network, today announced the launch of its new comprehensive cancer hospital in Byatarayanapura (Hebbal), ....
Monitoring Agency Report for the quarter ended March 31, 2026- in relation to the Rights Issue of the Company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Motilal Oswal BSE Healthcare ETF & Others
Further to the intimation submitted to Stock Exchanges dated May 01, 2026, with respect to the meeting of the Board of Directors of the Company, to be held on Tuesday, May 19, 2026, inter-alia ....
Healthcare Global Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.
The Company has informed the Exchange about completion of acquisition of additional 34% shares of Vizag Hospital and Cancer Research Centre Private Limited (Vizag Hospital). With this acquisition, ....
Intimation of closure of Trading Window under the SEBI (Prohibition of Insider Trading) Regulations, 2015, for the quarter and financial year ending on March 31, 2026.
Newspaper Advertisements in respect of certain matters such as details of subscription, basis of allotment and date of credit of equity shares pursuant to the Rights Issue of the Company.
Newspaper Advertisement in respect of Special Window for Transfer and Dematerialization of Physical Securities of the Company.
Annual Reports
10Credit Ratings
6Concalls
50Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Dec 2025
31 Dec 2025Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Mar 2025
31 Mar 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Nov 2022
30 Nov 2022Oct 2022
31 Oct 2022Sep 2022
30 Sept 2022Aug 2022
31 Aug 2022May 2022
31 May 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Sep 2020
30 Sept 2020Jul 2020
31 Jul 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Jan 2020
31 Jan 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019Jun 2019
30 Jun 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Aug 2016
31 Aug 2016Jun 2016
30 Jun 2016Held by ETFs
3 ETFs hold HCG · sorted by weight
Held by Mutual Funds
27 schemes hold HCG · sorted by weight